Clean area

Who is novosanis

Novosanis is a wholly owned subsidiary of OraSure Technologies Inc (NASDAQ: OSUR) and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology.

Read more
Colli Pee Novosanis

Our products

Improving the quality of diagnostics by volumetric self-sampling of first-void (first catch) urine

Learn more
Colli-Pee postal kits for home collection

Home collection

Improving the quality of home-based urine collection by easy self-sampling, alongside postal packaging

Learn more

Latest news

View all news

Winner announcement of EACR & Novosanis Research Grant: Cancer Biomarker Detection in Urine

12/10/2021
We are pleased to announce that Dr Barbara Guinn from University of Hull UK is the winner of the EACR & Novosanis Grant for Cancer Biomarker Detection in Urine.
Read more

Latest blogpost

View all blogs

Urine: a promising sample type to detect and monitor prostate cancer

Urine as an emerging liquid biopsy for prostate cancer biomarker detection

25/11/2021
Finding new and specific biomarkers for prostate cancer can improve cancer detection and overall patient outcomes. The increasing knowledge of multi-omics has great potential for prostate cancer research. Several biomarker candidates have been identified in urine
Read more

Upcoming event

View all events

Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2022

Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2022

Rotterdam, The Netherlands
Novosanis will be attending the Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2022 conference on March 1 & 2. The conference will focus on the development of liquid biopsies utilizing circulating cell-free DNA (cfDNA), circulating tumour cells (CTCs) and other biomarkers found in...
Read more